GLP-1RA vs DPP-4i Use and Rates of Hyperkalemia and RAS Blockade Discontinuation in Type 2 Diabetes.
GLP-1RA 與 DPP-4i 在 2 型糖尿病中使用及高鉀血症與 RAS 阻斷劑停用的比率。
JAMA Intern Med 2024-08-12
Risk of hyperkalaemia in patients with type 2 diabetes mellitus prescribed with SGLT2 versus DPP-4 inhibitors.
糖尿病患者使用SGLT2與DPP-4抑制劑時高鉀血症的風險。
Eur Heart J Cardiovasc Pharmacother 2024-01-16
Once-weekly glucagon-like peptide-1 receptor agonists vs dipeptidyl peptidase-4 inhibitors: cardiovascular effects in people with diabetes and cardiovascular disease.
每週一次的胰高血糖素樣肽-1受體激動劑 vs 二肽基胜肽酶-4抑制劑：對患有糖尿病和心血管疾病的人的心血管效應。
Cardiovasc Diabetol 2024-03-13
A population-based cohort defined risk of hyperkalemia after initiating SGLT-2 inhibitors, GLP1 receptor agonists or DPP-4 inhibitors to patients with chronic kidney disease and type 2 diabetes.
慢性腎臟病和2型糖尿病患者在開始使用SGLT-2抑制劑、GLP-1受體激動劑或DPP-4抑制劑後，高鉀血症風險的基於人口的群體研究。
Kidney Int 2024-03-10
Cardiovascular and renal outcomes of GLP-1 receptor agonists vs. DPP-4 inhibitors and basal insulin in type 2 diabetes mellitus: A systematic review and meta-analysis.
GLP-1 受體激動劑與 DPP-4 抑制劑及基礎胰島素在第2型糖尿病的心血管和腎臟結果：系統性回顧與荟萃分析。
Diab Vasc Dis Res 2024-01-02
研究發現，GLP-1 RA 在管理 2 型糖尿病時，對心血管和腎臟效果比 DPP4i 和基礎胰島素更好。GLP-1 RA 較 DPP4i 有較大好處，包括心肌梗塞、中風、心血管死亡和全因死亡。與基礎胰島素相比，GLP-1 RA 在心血管和全因死亡方面也更有效。總結來說，使用 GLP-1 RA 可能比 DPP4i 和基礎胰島素對心腎結果更有益。
PubMedDOI
Comparison of GLP-1 receptor agonists and other Glucose-Lowering agents on cardiovascular outcomes in individuals with type 2 diabetes and Obesity: A Spanish Real-World Population-Based study.
GLP-1受體激動劑與其他降糖藥物在2型糖尿病和肥胖患者心血管結果上的比較：西班牙真實世界人口研究。
Diabetes Res Clin Pract 2024-02-16
Glucagon-like-peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes in diabetes in relation to achieved glycemic control. A Danish nationwide study.
糖尿病患者中胰高血糖素樣肽-1受體激動劑與二肽基胺基肽酶-4抑制劑，以及心血管結果之比較，與達到的血糖控制相關的丹麥全國性研究。
J Diabetes 2024-05-18
SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors and risk of hyperkalemia among people with type 2 diabetes in clinical practice: population based cohort study.
SGLT-2抑制劑、GLP-1受體激動劑和DPP-4抑制劑在臨床實踐中對2型糖尿病患者高鉀風險的人口基礎cohort研究。
BMJ 2024-06-26
Real-world impact of adding a glucagon-like peptide-1 receptor agonist compared with basal insulin on metabolic targets in adults living with type 2 diabetes and chronic kidney disease already treated with a sodium-glucose co-transporter-2 inhibitor: The Impact GLP-1 CKD study.
在已接受鈉-葡萄糖共轉運蛋白-2抑制劑治療的2型糖尿病及慢性腎病成人中，添加胰高血糖素樣肽-1受體激動劑與基礎胰島素對代謝目標的實際影響：Impact GLP-1 CKD 研究。
Diabetes Obes Metab 2024-08-08
Kidney and Cardiovascular Effectiveness of SGLT2 Inhibitors vs GLP-1 Receptor Agonists in Type 2 Diabetes.
SGLT2 抑制劑與 GLP-1 受體激動劑在 2 型糖尿病中的腎臟與心血管效果比較。
J Am Coll Cardiol 2024-08-14